In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is moving to an online platform or postponing all meetings and events intended to be held in person through April 30, 2020. Please check here for more information, including Academy programs on COVID-19, and links to the latest advisories from public health officials.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Bioethics Meets R&D: The Ethics of Pre-approval Access

June 02, 2016

Bioethics Meets R&D: The Ethics of Pre-approval Access
The Division of Medical Ethics at NYU School of Medicine and the Academy bring together patients, regulators, manufacturers, journalists, and experts to debate the difficult ethical issues surrounding “compassionate use” of pre-approved medicines.

Patients with life-threatening illnesses face challenges in accessing potential therapies at the cutting-edge of R&D which have not yet been proven in a clinical trial. Some pharmaceutical companies produce and provide medicines on a case-by-case basis through expanded access or "compassionate use" programs. The tension among principles of fairness, equity, and compassion are explored in this podcast through a case study about a social media campaign led to an expedited clinical trial for an investigative antiviral medicine. Guests will explore the provocative and emotional stories of patients, family members, advocates, researchers, physicians, and the regulators charged with keeping medicines in the marketplace safe and effective.